Wyeth Bests Pa. Fen-Phen Hypertension Suit

Law360, New York (July 26, 2010, 4:31 PM EDT) -- Saying Pennsylvania law does not recognize causes of action for negligently failing to test a drug or failing to withdraw it from the market, a state appeals court has affirmed the dismissal of a suit over Wyeth Inc.'s diet drug fen-phen.

The Superior Court of Pennsylvania issued a ruling Monday finding that the trial court had properly granted summary judgment in favor of Wyeth and against Marie Owens, who claimed the prescription drug, sold under the brand name Pondimin, caused her to develop primary pulmonary hypertension....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.